TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05440422: The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 45 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT05440422 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05440422 Rescue Dossier →